Group One Trading’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,600
| Closed | -$6.46K | – | 8002 |
|
|
2025
Q1 | $6.46K | Sell |
1,600
-56,300
| -97% | -$188K | ﹤0.01% | 6524 |
|
|
2024
Q4 | $185K | Buy |
+57,900
| New | +$196K | ﹤0.01% | 3993 |
|
|
2024
Q3 | – | Sell |
-9,200
| Closed | -$19.8K | – | 6715 |
|
|
2024
Q2 | $19.8K | Sell |
9,200
-42,200
| -82% | -$75.1K | ﹤0.01% | 5238 |
|
|
2024
Q1 | $105K | Buy |
51,400
+37,300
| +265% | +$74.4K | ﹤0.01% | 4109 |
|
|
2023
Q4 | $32.3K | Buy |
14,100
+13,900
| +6,950% | +$30.3K | ﹤0.01% | 5385 |
|
|
2023
Q3 | $340 | Sell |
200
-8,900
| -98% | -$20.2K | ﹤0.01% | 7383 |
|
|
2023
Q2 | $22.5K | Buy |
9,100
+4,600
| +102% | +$12.6K | ﹤0.01% | 5917 |
|
|
2023
Q1 | $10.1K | Sell |
4,500
-2,000
| -31% | -$10K | ﹤0.01% | 5928 |
|
|
2022
Q4 | $33.2K | Buy |
6,500
+4,660
| +253% | +$33.6K | ﹤0.01% | 5274 |
|
|
2022
Q3 | $19K | Sell |
1,840
-2,460
| -57% | -$29.3K | ﹤0.01% | 6095 |
|
|
2022
Q2 | $44K | Sell |
4,300
-470
| -10% | -$6.16K | ﹤0.01% | 5668 |
|
|
2022
Q1 | $84K | Buy |
+4,770
| New | +$102K | ﹤0.01% | 5658 |
|
Group One Trading's CKPT Position: Q2 2025 in Review
Group One Trading sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 25,632 shares — an estimated $104K sold.
Group One Trading first reported a position in CKPT in Q3 2021 and held it in 8 quarters. The position peaked at $311K in Q1 2022. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Group One Trading reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Group One Trading sold 25,632 Checkpoint Therapeutics shares in Q2 2025, an estimated $104K.
- Group One Trading first reported a position in Checkpoint Therapeutics in Q3 2021 and held it in 8 quarters.
- Group One Trading's Checkpoint Therapeutics position peaked at $311K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Group One Trading's 13F filing for Q2 2025, filed 14 Aug 2025.